Remove Definition Remove FDA Remove Licensing
article thumbnail

HHS Recommends Re-Classification of Marijuana as a Schedule III Controlled Substance – A Bellwether for the Future of Cannabis-ness

Health Law Advisor

The DEA has the final authority to reschedule a drug and will now initiate its own review of marijuana, a process that does not have any definitive timeline but could be moved along if determined to be an agency priority. In addition, only certain components of FDA’s eight-factor analysis bind the DEA. heroin, LSD, and ecstasy).

FDA 111
article thumbnail

FDA Finalizes Guidance on Combination Products

C&M Health Law

Food & Drug Administration (FDA) published a notice in the Federal Register announcing the availability of a final guidance for industry and FDA staff entitled “Principles of Premarket Pathways for Combination Products”. The final guidance is available on the FDA’s website. On January 31, 2022, the U.S.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives

Healthcare Law Blog

It remains to be seen whether subsequent regulations will further clarify the applicability of this law to certain individual roles that may not neatly fall within the Act’s definitions. An applicant will also need to satisfy certain prelicensure requirements and complete continuing education to maintain their license.

article thumbnail

From Discretion to Regulation: What FDA’s Final Rule Means for Laboratory Developed Tests

Hall Render

In April 2024, the Food and Drug Administration (“FDA”) issued a Final Rule amending the definition of in vitro diagnostics products (“IVDs”) found in 21 C.F.R. The FDA notes that it will continue to exercise enforcement discretion during the review of premarket submissions received by this stage.

FDA 40
article thumbnail

XRHealth and Amelia Virtual Care Announce Merger, Creating the Largest XR Therapeutics Platform in the World

Healthcare IT Today

The completion of the merger is subject to the execution of definitive contracts by the parties, as well as to the satisfaction of certain conditions customary in this kind of transaction including the approval by the shareholders of both companies. Sanfeliu, Managing Partner at Asabys.

article thumbnail

Is CMS Ignoring the Realities of Biopharmaceutical Costs?

Health Law Advisor

It seeks to exclude costs of ongoing research and, while studies have recognized that R&D costs are significant for international roll-outs and line extensions, the guidance credits only studies for FDA purposes. At the same time, in calculating the recoupment of these US costs, it uses global to total lifetime net revenue.

FDA 52
article thumbnail

Understanding the 2025 Medicare Part D Re-design: What You Need to Know

Innovaare Compliance

6] A compound drug not approved by the FDA under a New Drug Application or Biological License Application does not meet the definition of an applicable drug and will not be eligible for Part D. Rebates from the selected drugs may change. Additional drugs will be selected for negotiation every year after 2025. [6]